Bouchey Financial Group Ltd Grows Holdings in Danaher Co. (NYSE:DHR)

Bouchey Financial Group Ltd increased its position in shares of Danaher Co. (NYSE:DHR) by 60.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,290 shares of the conglomerate’s stock after purchasing an additional 486 shares during the quarter. Bouchey Financial Group Ltd’s holdings in Danaher were worth $296,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DHR. FMR LLC boosted its holdings in Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Danaher by 6,862.7% during the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock worth $213,452,000 after purchasing an additional 916,513 shares during the last quarter. Proficio Capital Partners LLC boosted its holdings in Danaher by 29,287.7% during the fourth quarter. Proficio Capital Partners LLC now owns 588,929 shares of the conglomerate’s stock worth $135,189,000 after purchasing an additional 586,925 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares during the last quarter. Finally, Fisher Funds Management LTD purchased a new position in Danaher during the fourth quarter worth about $120,718,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Danaher stock opened at $205.69 on Friday. The firm’s 50 day simple moving average is $225.00 and its 200 day simple moving average is $245.50. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $147.01 billion, a PE ratio of 38.96, a price-to-earnings-growth ratio of 2.66 and a beta of 0.83. Danaher Co. has a 1-year low of $196.80 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the firm posted $2.09 EPS. As a group, analysts expect that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date is Friday, March 28th. This is a positive change from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio is 24.24%.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DHR. Guggenheim initiated coverage on shares of Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price target on the stock. Wells Fargo & Company lowered their price objective on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. JPMorgan Chase & Co. lowered their price objective on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Barclays lowered their price objective on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Finally, Jefferies Financial Group lowered their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Seven analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.